Bruker Corporation $BRKR Shares Sold by Legal & General Group Plc

Legal & General Group Plc cut its stake in Bruker Corporation (NASDAQ:BRKR) by 21.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,315 shares of the medical research company’s stock after selling 43,599 shares during the period. Legal & General Group Plc’s holdings in Bruker were worth $7,647,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Allworth Financial LP increased its holdings in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the period. Covestor Ltd grew its holdings in Bruker by 304.6% during the fourth quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock worth $67,000 after acquiring an additional 1,066 shares during the period. CWM LLC grew its holdings in Bruker by 49.8% during the fourth quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after acquiring an additional 542 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Bruker by 79.7% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock valued at $86,000 after purchasing an additional 1,230 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Bruker by 51.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 942 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $56.39 on Friday. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.54. The firm has a market capitalization of $8.58 billion, a PE ratio of -234.96, a PEG ratio of 1.92 and a beta of 1.31. The business’s 50 day moving average is $42.57 and its 200-day moving average is $43.45. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. The company had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.Bruker’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts predict that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, June 22nd. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker’s payout ratio is currently -83.33%.

Wall Street Analyst Weigh In

BRKR has been the subject of a number of recent analyst reports. Citigroup increased their price target on Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. TD Cowen lifted their price target on Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a report on Thursday, May 7th. The Goldman Sachs Group reduced their price target on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a report on Friday, February 13th. Stifel Nicolaus set a $45.00 price objective on Bruker in a research note on Friday, May 8th. Finally, Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $50.54.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 27.20% of the stock is currently owned by corporate insiders.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.